Q1 EPS Estimates for Beta Bionics Reduced by Leerink Partnrs

Beta Bionics, Inc. (NASDAQ:BBNX) – Investment analysts at Leerink Partnrs lowered their Q1 2025 EPS estimates for shares of Beta Bionics in a research note issued on Wednesday, March 26th. Leerink Partnrs analyst M. Kratky now forecasts that the company will earn ($0.51) per share for the quarter, down from their prior forecast of ($0.50). Leerink Partnrs has a “Strong-Buy” rating on the stock. Leerink Partnrs also issued estimates for Beta Bionics’ Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.83) EPS and FY2027 earnings at ($2.27) EPS.

Beta Bionics (NASDAQ:BBNX) last released its earnings results on Tuesday, March 25th. The company reported ($1.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($1.40). The company had revenue of $20.44 million during the quarter, compared to analyst estimates of $20.01 million.

Several other brokerages have also recently commented on BBNX. Leerink Partners assumed coverage on Beta Bionics in a research report on Monday, February 24th. They issued an “outperform” rating and a $28.00 target price for the company. Baird R W upgraded shares of Beta Bionics to a “hold” rating in a research report on Thursday, February 20th. LADENBURG THALM/SH SH initiated coverage on shares of Beta Bionics in a research report on Thursday, February 20th. They issued a “neutral” rating and a $20.00 price target for the company. Piper Sandler initiated coverage on Beta Bionics in a report on Monday, February 24th. They set an “overweight” rating and a $26.00 price objective on the stock. Finally, Lake Street Capital started coverage on Beta Bionics in a report on Monday, February 24th. They issued a “buy” rating and a $30.00 target price for the company. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $24.83.

Beta Bionics Trading Down 3.7 %

Shares of NASDAQ:BBNX opened at $12.67 on Friday. Beta Bionics has a 1-year low of $12.11 and a 1-year high of $24.50.

Insider Transactions at Beta Bionics

In other news, insider Mike Mensinger purchased 33,350 shares of the stock in a transaction on Friday, January 31st. The stock was purchased at an average price of $17.00 per share, for a total transaction of $566,950.00. Following the acquisition, the insider now owns 59,019 shares in the company, valued at $1,003,323. This trade represents a 129.92 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Hadley Harbor Aggre Wellington acquired 1,000,000 shares of Beta Bionics stock in a transaction dated Friday, January 31st. The stock was purchased at an average cost of $17.00 per share, for a total transaction of $17,000,000.00. Following the completion of the purchase, the insider now owns 3,901,599 shares in the company, valued at approximately $66,327,183. The trade was a 34.46 % increase in their position. The disclosure for this purchase can be found here.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.